Injection of Doxorubicin-Carrying Liquid-Solid Phase Variant in Situ Gel for the Treatment of Rabbit Residual VX2 Liver Cancer after HIFU Irradition

YAO Jin-peng,DAI Li-li,LI Juan,ZHENG Yuan-yi,JIANG Ling,LU Guang-ming,FENG Xiao-xia,WANG Zhi-gang
DOI: https://doi.org/10.13929/j.1672-8475.2012.11.018
2012-01-01
Abstract:Objective To assess the curative effect of injection of doxorubicin-carrying liquid-solid phase variant in situ gel for residual rabbit VX2 liver cancer after high intensity focused ultrasound(HIFU) irradiation.Methods VX2 liver tumor mode1s were set up in 24 rabbits,and non-complete HIFU ablation was performed.The rabbits were randomly divided into 2 groups(each n=12),i.e.HIFU+DOX-ISFI group(injecting doxorubicin-carrying liquid-solid phase variant in situ gel after HIFU irradiation) and HIFU+N-ISFI group(injecting drug-free liquid-solid phase variant in situ gel after HIFU irradiation).Tumor growth rate and PCNA expression were compared between the two groups.The distribution of drug in cancer was observed with a fluorescent imager of frozen tissue samples.Results Tumor growth rate of HIFU+DOX-ISFI group was obviously lower than that of HIFU+N-ISFI group(P0.05).Proliferating index of HIFU+DOX-ISFI group was dramatically lower than that of HIFU+N-ISFI group(P0.05).Fluorescence imaging showed the drug distributed from the injection center to the surrounding area,like a ladder shape.Conclusion Injection of doxorubicin-carrying liquid-solid phase variant in-situ gel can effectively treat the residual rabbit VX2 liver cancer after HIFU treatment.
What problem does this paper attempt to address?